Sign up Australia
Proactive Investors - Run By Investors For Investors

Holista CollTech teams with North American noodle manufacturer

Holista CollTech Ltd (ASX:HCT) will conduct joint research with Wing’s Food Products, a major North American noodle manufacturer, to develop the world’s first low-Glycemic Index (low-GI) noodles.
Holista CollTech teams with North American noodle manufacturer
Holista CollTech Ltd teams with North American noodle manufacturer

Holista Foods has developed PANATURA, a breakthrough natural formula which, when added to white flour, dramatically reduces blood sugar levels without changing the taste of the final product.

Based in Ontario and Alberta, Canada, Wing’s has supplied noodles to the North American market since 1953.

Wing’s will test Holista’s low-GI ingredient for use in noodles and Holista will provide expertise on the application of its formula.

The final product will be independently tested at GI-Labs, a nutrition research organization in Toronto, Canada.

Once validated, Wing’s and Holista Foods will enter a commercial agreement to manufacture and distribute the low-GI noodles in North America.

Holista Foods is a 51-49 joint-venture company set-up between Holista and Nadja Foods LLC.

According to market research group Statista, almost 50% of the world’s wheat is consumed as noodles, led by China and Indonesia, respectively.

In comparison, only a quarter of the world’s wheat is consumed as bread.

In 2015, the global demand for instant noodles amounted to 103.58 billion servings.

The low-GI movement is gaining traction as consumers are getting educated on making healthy food choices to tackle the global pandemic of obesity and diabetes.





Register here to be notified of future HCT Company articles
View full HCT profile View Profile

Holista Colltech Ltd Timeline

Newswire
September 19 2017

Related Articles

man at a micrscope
September 29 2017
The company is a specialist in the storage of stems cells from the umbilical cord, which could provide a potentially life-saving treatment for 82 blood-borne diseases
1-Operation.jpg
January 19 2017
Deltex’s overseas sales are booming but its previously dominant NHS revenues are dropping off
ventripoint_device.png
June 22 2017
The device can give accurate and rapid volumetric information about all four chambers of the heart

No investment advice

The information on this Site is of a general nature only. It does not take your specific needs or circumstances into consideration, so you should look at your own financial position, objectives and requirements and seek financial advice before making any financial decisions. You acknowledge and understand that neither the Company, its related bodies corporate, the information providers or their affiliates will advise you personally about the nature, potential value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter. You should read our FSG and any other relevant disclosure documents and if necessary seek persona advice prior to making any investment decision.

You understand and agree that no Content (as defined below) published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person.

You understand that in certain circumstances the Company, its related bodies corporate, the information providers or their affiliates may have received, or be entitled to receive, financial or other consideration in connection with promoting, and providing information about, certain entities on the Site and in communications otherwise provided to you.

You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate. From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Before you act on any general advice we provide, please consider whether it is appropriate for your personal circumstances.

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use